AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth

Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing therapeutic area

Read more at globenewswire.com